Considering the heterogeneity of breast cancer subtypes, GR has been implicated in driving the progression and metastasis of ER‐negative disease (West et al, 2018; Obradović et al, 2019), which accounts for approximately 15% of all breast cancers (Colleoni et al, 2016; Esserman et al, 2017; Pan et al, 2017; Lindström et al, 2018; Nancy et al, 2019). Here, NR3C1 is linked to breast carcinoma.